118 4 Cell <strong>Specific</strong> Delivery of Anti-Inflammatory <strong>Drug</strong>s to Hepatic Cells [91] Chaudhuri G, Mukhopadhyay A, Basu SK, Biochem. Pharmacol. 1989, 38, 2995–3002. [92] Ogawara K, Hasegawa S, Nishikawa M, Takakura Y, Hashida M, J. <strong>Drug</strong>. Target. 1999, 6, 349–360. [93] Melgert BN, Weert B, Molema G, Meijer DKF, Poelstra K, Hepatology 1999, 30, 329A. [94] Skogh T, Stendahl O, Sundqvist T, Edebo L, Int. Arch. Allergy Appl. Immunol. 1983, 70, 238–244. [95] Rooijen Nv, Sanders A, Int. J. Pharm. 1998, 162, 45–50. [96] Daemen T, Hofstede G, Ten Kate MT, Bakker-Woudenberg IAJM, Scherphof GL, Int. J. Cancer 1995, 61, 716–721. [97] Kole L, Das L, J. Infect. Dis. 1999, 180, 811–820. [98] Coukell AJ, Brogden RN, <strong>Drug</strong>s 1998, 55, 585–612. [99] Thomas K, Nijenhuis AM, Dontje BH, Daemen T, Scherphof GL, Clin. Exp. Metast. 1995, 13, 328–336. [100] Harashima H, Sakata K, Funato K, Kiwada H, Pharm. Res. 1994, 11, 402–406. [101] Rossi JD, Wallace BA, J. Biol. Chem. 1983, 258, 3327–3331. [102] Liu DX, Adv. <strong>Drug</strong>. Deliv. Rev. 1997, 24, 201–213. [103] Scherphof GL, Kamps JAAM, Adv. <strong>Drug</strong>. Deliv. Rev. 1998, 32, 81–97. [104] Kamps JA, Morselt HW, Scherphof GL, Biochem. Biophys. Res. Commun. 1999, 256, 57–62. [105] Kamps JAAM, Morselt HWM, Swart PJ, Meijer DKF, Scherphof GL, Proc. Natl Acad. Sci. USA 1997, 94, 11681–11685. [106] Bijsterbosch MK, Van Berkel TJC, Adv. <strong>Drug</strong>. Deliv. Rev. 1990, 5, 231–251. [107] De Rijke YB, Biessen EA, Vogelezang CJ, Van Berkel TJ, Biochem. J. 1994, 304, 69–73. [108] Kuiper J, Bakkeren HF, Biessen EAL, Van Berkel TJC, Biochem. J. 1994, 299, 285–290. [109] Firestone RA, Pisano JM, Falck JR, McPhaul MM, Krieger M, J. Med. Chem. 1984, 27, 1037–1043. [110] van de Water B, Van Berkel TJC, Kuiper J, Mol. Pharmacol. 1994, 45, 971–977. [111] Kuipers ME, Van den Berg M, Swart PJ, Laman JD, Meijer DKF, Koppelman MHGM, Huisman H, Biochem. Pharmacol. 1999, 57, 889–898. [112] Swart PJ, Hirano T, Kuipers ME, Ito Y, Smit C, Hashida M, Nishikawa M, Beljaars L, Meijer DKF, Poelstra K, J. Hepatol. 1999, 30, 1034–1043. [113] Takakura Y, Masuda S, Tokuda H, Nishikawa M, Hashida M, Biochem. Pharmacol. 1994, 47, 853- 858. [114] Poelstra K, Bakker WW, Klok PA, Kamps JA, Hardonk MJ, Meijer DKF, Am. J. Pathol. 1997, 151, 1163–1169. [115] Poelstra K, Grasmeijer R, Meijer DKF, Hepatology 1996, 24, 327A. [116] Nolan JP, Hepatology 1989, 10, 887–891. [117] Beljaars L, Molema G, Schuppan D, Geerts A, De Bleser PJ, Weert B, Meijer DKF, Poelstra K, J. Biol. Chem. 2000, 275, 12743–12751. [118] Beljaars L, Molema G, Weert B, Bonnema H, Olinga P, Groothuis GMM, Meijer DKF, Poelstra K, Hepatology 1999, 29, 1486–1493. [119] De Bleser PJ, Jannes P, Van Buul-Offers SC, Hoogerbrugge CM, Van Schravendijk CFH, Niki T, Rogiers V, Van den Brande JL, Wisse E, Geerts A, Hepatology 1995, 21, 1429–1437. [120] Weiner JK, Chen AP, Davis BH, J. Biol. Chem. 1998, 273, 15913–15919. [121] Smith WL, Am. J. Physiol. 1992, 263, F181–F191. [122] Goodman A, Gilman AZ, In: Goodman and Gilman’s the pharmacological basis of therapeutics. McGraw-Hill, Inc., New York, 1993. [123] Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, Murphy M, Vessey MP, Colin-Jones DG, Lancet 1994, 343, 1075–1078. [124] Gentilini P, Cirrhosis, J. Hepatol. 1993, 19, 200–203. [125] Endoh T, Tang Q, Denda A, Noguchi O, Kobayashi E, Tamura K, Horiguchi K, Ogasawara H, Tsujiuchi T, Nakae D, Sugimura M, Konishi Y, Carcinogenesis 1996, 17, 467–475. [126] Badger AM, Olivera D, Talmadge JE, Hanna N, Circ. Shock 1989, 27, 51–61. [127] Wise WC, Cook JA, Eller T, Halushka PV, J. Pharmacol. Exp. Ther. 1980, 215, 160–164. [128] Lin RS, Lee FY, Lee SD, Tsai YT, Lin HC, Lu RH, Hsu WC, Huang CC, Wang SS, Lo KJ, J. Hepatol. 1995, 22, 165–172. [129] Nolan JP, Hepatology 1981, 1, 458–465. [130] Boyer TD, Zia P, Reynolds TB, Gastroenterolgy 1979, 77, 215–222. [131] Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE, Ann. Intern. Med. 1993, 119, 1198–1208. [132] Sternberg EM, Wilder RL, In: Arthritis and Allied Conditions (Eds McCarthy DJ, Koopman WJ), pp. 665–682. Lea & Febiger, Philadelphia, 1993.
References 119 [133] Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G, Proc. Natl Acad. Sci. USA 1992, 89, 9991–9995. [134] Zimmerman GA, Prescott SM, McIntyre TM, Immunol. Today 1992, 13, 93–100. [135] Coulpier M, Andreev S, Lemercier C, Dauchel H, Lees O, Fontaine M, Ripoche J, Clin. Exp. Immunol. 1995, 101, 142–149. [136] Didonato JA, Saatcioglu F, Karin M, Am. J. Respir. Crit. Care Med. 1996, 154, S11–5. [137] Auphan N, Didonato JA, Rosette C, Helmberg A, Karin M, Science 1995, 270, 286–290. [138] Sheppard KA, Phelps KM, Williams AJ, Thanos D, Glass CK, Rosenfeld MG, Gerritsen ME, Collins T, J. Biol. Chem. 1998, 273, 29291–29294. [139] Chanarin N, Johnston SL, <strong>Drug</strong>s 1994, 47, 12–24. [140] Brooks PM, Agents Actions (Suppl.), 1993, 44, 161–163. [141] Muller R, J. Med. 1981, 12, 209–235. [142] Sullivan GW, Carper HT, Novick Jr WJ, Mandell GL, Infect. Immun. 1988, 56, 1722–1729. [143] Ward A, Clissold SP, <strong>Drug</strong>s 1987, 34, 50–97. [144] Windmeier C, Gressner AM, Gen. Pharmacol. 1997, 29, 181–196. [145] Schuppan D, Strobel D, Hahn EG, Digestion 1998, 59, 385–39 [146] Niki T, Rombouts K, De Bleser PJ, de Smet K, Rogiers V, Schuppan D, Yoshida M, Gabbiani G, Geerts A, Hepatology 1999, 29, 858–867. [147] Albrecht C, Meijer DKF, Lebbe C, Sägesser H, Melgert BN, Poelstra K, Reichen J, Hepatology. 1997, 26, 1553–1559. [148] Melgert BN, Wartna E, Lebbe C, Albrecht C, Molema G, Poelstra K, Reichen J, Meijer DKF, J. <strong>Drug</strong> Target. 1998, 5, 329–342. [149] Albrecht C, Melgert BN, Reichen J, Poelstra K, Meijer DKF, J. <strong>Drug</strong> Target. 1998, 6, 105–117. [150] Melgert BN, Poelstra K, Jack VK, Molema G, Meijer DKF, Hepatology 1998, 28, 440A. [151] Rosenmund A, Kuyas C, Heberli A, Biochem. J. 1986, 240, 239–245. [152] Melgert BN, Olinga P, Jack VK, Molema G, Meijer DKF, Poelstra K, J. Hepatol. 2000, 32, 603–611. [153] Noda T, Mimura H, Orita K, Hepatogastroenterology 1990, 37, 319–323. [154] Petermann H, Heymann S, Vogl S, Dargel R, J. Hepatol. 1996, 24, 468–477. [155] Laurent TC, Laurent UB, Fraser JR, Ann. Med. 1996, 28, 241–253. [156] Weiner JA, Chen A, Davis BH, J. Biol. Chem. 1998, 273, 15913–15919. [157] Wong L, Yamasaki G, Johnson RJ, Friedman SL, J. Clin. Invest. 1994, 94, 1563–1569. [158] Kountouras J, Billing BH, Scheuer PJ, Br. J. Exp. Pathol. 1984, 65, 305–311. [159] Fischer-Nielsen A, Poulsen HE, Hansen BA, Hage E, Keiding S, J. Hepatol. 1991, 12, 110–117. [160] Boigk G, Stroedter L, Herbst H, Waldschmidt J, Riecken EO, Schuppan D, Hepatology 1997, 26, 643–649. [161] Braet F, De Zanger R, Sasaoki T, Baekeland M, Janssens P, Smedsrod B, Wisse E, Lab. Invest. 1994, 70, 944–952. [162] Geerts A, Niki T, Hellemans K, De Craemer D, Van den Berg K, Lazou J-M, Stange G, Van de Winkel M, De Bleser PJ, Hepatology 1998, 27, 590–598. [163] Dong QG, Bernasconi S, Lostaglio S, De Calmanovici RW, Martin Padura I, Breviario F, Garlanda C, Ramponi S, Mantovani A, and Vecchi A, Arterioscler. Thromb. Vasc. Biol. 1997, 17, 1599–1604. [164] Kuiper J, Brouwer A, Knook DL, Van Berkel TJC, In: The Liver: Biology and Pathobiology (Eds Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA), pp. 791–818. Raven Press Ltd., New York, 1994. [165] Melgert BN, Olinga P, Weert B, Slooff MJH, Meijer DKF, Poelstra K, Groothuis GMM, <strong>Drug</strong> Metab. Dispos. 2001, 29, 361–367. [166] Olinga P, Meijer DKF, Slooff MJH, Groothuis GMM, Toxicol. In Vitro 1997, 12, 77–100. [167] Yamashiro DJ, Maxfield FR, J. Cell Biochem. 1984, 26, 231–246. [168] Geuze HJ, Slot JW, Strous GJAM, Lodish HF, Schwartz AL, Cell 1983, 32, 1277–1287. [169] De Duve C, Wattiaux R, Annu. Rev. Physiol. 1966, 28, 435–492. [170] Thorens B, Vassalli P, Nature 1986, 321, 618–620. [171] Clarke BL, Weigel PH, Biochem. J. 1989, 262, 277–284. [172] Goltz JS, Wolkoff AW, Novikoff PM, Stockert RJ, Satir P, Proc. Natl Acad. Sci. USA 1992, 89, 7026–7030. [173] Lebbe C, Reichen J, Wartna E, Sägesser H, Poelstra K, and Meijer DKF, J. <strong>Drug</strong> Target. 1997, 4, 303–310. [174] Beljaars L, Poelstra K, Molema G, Meijer DKF, J. Hepatol. 1998, 29, 579–588.
- Page 1 and 2:
Drug Targeting Organ-Specific Strat
- Page 3 and 4:
Drug Targeting Organ-Specific Strat
- Page 5 and 6:
Preface Drug Targeting Organ-Specif
- Page 7 and 8:
Foreword Drug Targeting Organ-Speci
- Page 9 and 10:
X List of Contributors Henderik W.
- Page 11 and 12:
XII List of Contributors Grietje Mo
- Page 13 and 14:
Contents Drug Targeting Organ-Speci
- Page 15 and 16:
Contents XVII 3 Pulmonary Drug Deli
- Page 17 and 18:
Contents XIX 5.2.1.6 Identification
- Page 19 and 20:
Contents XXI 7.5 In Vitro Technique
- Page 21 and 22:
Contents XXIII 9.4 Tumour Vasculatu
- Page 23 and 24:
Contents XXV 12.8. Tissue Slices fr
- Page 25 and 26:
Drug Targeting Organ-Specific Strat
- Page 27 and 28:
Dexa dexamethasone DIVEMA divinyl e
- Page 29 and 30:
LRP lung resistance related protein
- Page 31 and 32:
ROS reactive oxygen species RSV res
- Page 33 and 34:
Index a ADEPT 217, 224, 268, 291 ad
- Page 35 and 36:
e E. coli expression system 292 eff
- Page 37 and 38:
polymers, soluble 4, 218 - dendrime
- Page 39 and 40:
2 1 Drug Targeting: Basic Concepts
- Page 41 and 42:
4 1 Drug Targeting: Basic Concepts
- Page 43 and 44:
6 1 Drug Targeting: Basic Concepts
- Page 45 and 46:
8 1 Drug Targeting: Basic Concepts
- Page 47 and 48:
10 1 Drug Targeting: Basic Concepts
- Page 49 and 50:
12 1 Drug Targeting: Basic Concepts
- Page 51 and 52:
14 1 Drug Targeting: Basic Concepts
- Page 53 and 54:
16 1 Drug Targeting: Basic Concepts
- Page 55 and 56:
18 1 Drug Targeting: Basic Concepts
- Page 57 and 58:
20 1 Drug Targeting: Basic Concepts
- Page 59 and 60:
22 1 Drug Targeting: Basic Concepts
- Page 61 and 62:
24 2 Brain-Specific Drug Targeting
- Page 63 and 64:
26 2 Brain-Specific Drug Targeting
- Page 65 and 66:
28 2 Brain-Specific Drug Targeting
- Page 67 and 68:
30 2 Brain-Specific Drug Targeting
- Page 69 and 70:
32 2 Brain-Specific Drug Targeting
- Page 71 and 72:
34 2 Brain-Specific Drug Targeting
- Page 73 and 74:
36 2 Brain-Specific Drug Targeting
- Page 75 and 76:
38 2 Brain-Specific Drug Targeting
- Page 77 and 78:
40 2 Brain-Specific Drug Targeting
- Page 79 and 80:
42 2 Brain-Specific Drug Targeting
- Page 81 and 82:
44 2 Brain-Specific Drug Targeting
- Page 83 and 84:
46 2 Brain-Specific Drug Targeting
- Page 85 and 86:
48 2 Brain-Specific Drug Targeting
- Page 87 and 88:
50 2 Brain-Specific Drug Targeting
- Page 89 and 90:
52 2 Brain-Specific Drug Targeting
- Page 91 and 92:
54 3 Pulmonary Drug Delivery: Deliv
- Page 93 and 94:
56 3 Pulmonary Drug Delivery: Deliv
- Page 95 and 96:
58 3 Pulmonary Drug Delivery: Deliv
- Page 97 and 98:
60 3 Pulmonary Drug Delivery: Deliv
- Page 99 and 100:
62 3 Pulmonary Drug Delivery: Deliv
- Page 101 and 102:
64 3 Pulmonary Drug Delivery: Deliv
- Page 103 and 104: 66 3 Pulmonary Drug Delivery: Deliv
- Page 105 and 106: 68 3 Pulmonary Drug Delivery: Deliv
- Page 107 and 108: 70 3 Pulmonary Drug Delivery: Deliv
- Page 109 and 110: 72 3 Pulmonary Drug Delivery: Deliv
- Page 111 and 112: 74 3 Pulmonary Drug Delivery: Deliv
- Page 113 and 114: 76 3 Pulmonary Drug Delivery: Deliv
- Page 115 and 116: 78 3 Pulmonary Drug Delivery: Deliv
- Page 117 and 118: 80 3 Pulmonary Drug Delivery: Deliv
- Page 119 and 120: 82 3 Pulmonary Drug Delivery: Deliv
- Page 121 and 122: 84 3 Pulmonary Drug Delivery: Deliv
- Page 123 and 124: 86 3 Pulmonary Drug Delivery: Deliv
- Page 125 and 126: 4 Cell Specific Delivery of Anti-In
- Page 127 and 128: The sinusoids are lined by the disc
- Page 129 and 130: 4.2.2.2 Phagocytosis and Transcytos
- Page 131 and 132: ther inflammatory cells or accessor
- Page 133 and 134: 4.3 Hepatic Inflammation and Fibros
- Page 135 and 136: process is not yet available. Sever
- Page 137 and 138: this carrier to the KCs.When the ma
- Page 139 and 140: e taken up rapidly by mannose recep
- Page 141 and 142: y the transcriptional regulatory pr
- Page 143 and 144: 4.8 Testing Liver Targeting Prepara
- Page 145 and 146: 4.8 Testing Liver Targeting Prepara
- Page 147 and 148: 4.9 Targeting of Anti-inflammatory
- Page 149 and 150: 4.9 Targeting of Anti-inflammatory
- Page 151 and 152: with monoclonal and bispecific anti
- Page 153: References 117 [50] Coleman DL, Eur
- Page 157 and 158: 5 Delivery of Drugs and Antisense O
- Page 159 and 160: 5.1 Introduction 123 convoluted tub
- Page 161 and 162: treatment of the targeted cell and
- Page 163 and 164: CL uptake (ml/min/g) centration pro
- Page 165 and 166: 5.2.1.4 Specific Binding of Alkylgl
- Page 167 and 168: 5.2 Renal Delivery Using Pro-Drugs
- Page 169 and 170: 5.2 Renal Delivery Using Pro-Drugs
- Page 171 and 172: 5.3 Renal Delivery Using Macromolec
- Page 173 and 174: 5.3 Renal Delivery Using Macromolec
- Page 175 and 176: 5.3 Renal Delivery Using Macromolec
- Page 177 and 178: 5.3 Renal Delivery Using Macromolec
- Page 179 and 180: 5.3 Renal Delivery Using Macromolec
- Page 181 and 182: 5.4 Renal Delivary of Antisense Oli
- Page 183 and 184: 5.4 Renal Delivery of Antisense Oli
- Page 185 and 186: 5.4.8 Benefits and Limitations of A
- Page 187 and 188: via reabsorption from the luminal s
- Page 189 and 190: References 153 [66] Franssen EJF, M
- Page 191 and 192: References 155 [145] Van Zwieten PA
- Page 193 and 194: 158 6 A Practical Approach in the D
- Page 195 and 196: 160 6 A Practical Approach in the D
- Page 197 and 198: 162 6 A Practical Approach in the D
- Page 199 and 200: 164 6 A Practical Approach in the D
- Page 201 and 202: 166 6 A Practical Approach in the D
- Page 203 and 204: 168 6 A Practical Approach in the D
- Page 205 and 206:
170 6 A Practical Approach in the D
- Page 207 and 208:
172 7 Vascular Endothelium in Infla
- Page 209 and 210:
174 7 Vascular Endothelium in Infla
- Page 211 and 212:
176 7 Vascular Endothelium in Infla
- Page 213 and 214:
178 7 Vascular Endothelium in Infla
- Page 215 and 216:
180 7 Vascular Endothelium in Infla
- Page 217 and 218:
182 7 Vascular Endothelium in Infla
- Page 219 and 220:
184 7 Vascular Endothelium in Infla
- Page 221 and 222:
186 7 Vascular Endothelium in Infla
- Page 223 and 224:
188 7 Vascular Endothelium in Infla
- Page 225 and 226:
190 7 Vascular Endothelium in Infla
- Page 227 and 228:
192 7 Vascular Endothelium in Infla
- Page 229 and 230:
194 7 Vascular Endothelium in Infla
- Page 231 and 232:
196 7 Vascular Endothelium in Infla
- Page 233 and 234:
8 Strategies for Specific Drug Targ
- Page 235 and 236:
8.2.2 Histogenesis The traditional
- Page 237 and 238:
may become obstructed and compresse
- Page 239 and 240:
8.5 Strategies to Deliver Drugs to
- Page 241 and 242:
8.5 Strategies to Deliver Drugs to
- Page 243 and 244:
larly cytotoxic immune effector cel
- Page 245 and 246:
contributes to limited tumour penet
- Page 247 and 248:
ples onto anti-EGP-2 scFv. Biologic
- Page 249 and 250:
In the case of drug-monoclonal anti
- Page 251 and 252:
cells, the presence of co-stimulato
- Page 253 and 254:
Monomethoxy-polyethylene glycol CH
- Page 255 and 256:
e efficiently loaded into the lipos
- Page 257 and 258:
8.6 Clinical Studies 223 Table 8.5.
- Page 259 and 260:
8.6.3 (Synthetic) (co)Polymers Solu
- Page 261 and 262:
8.8 Conclusions and Future Perspect
- Page 263 and 264:
References 229 [43] Chaouchi NA, Va
- Page 265 and 266:
References 231 [126] Czuczman MS, G
- Page 267 and 268:
234 9 Tumour Vasculature Targeting
- Page 269 and 270:
236 9 Tumour Vasculature Targeting
- Page 271 and 272:
238 9 Tumour Vasculature Targeting
- Page 273 and 274:
240 9 Tumour Vasculature Targeting
- Page 275 and 276:
242 9 Tumour Vasculature Targeting
- Page 277 and 278:
244 9 Tumour Vasculature Targeting
- Page 279 and 280:
246 9 Tumour Vasculature Targeting
- Page 281 and 282:
248 9 Tumour Vasculature Targeting
- Page 283 and 284:
250 9 Tumour Vasculature Targeting
- Page 285 and 286:
252 9 Tumour Vasculature Targeting
- Page 287 and 288:
254 9 Tumour Vasculature Targeting
- Page 289 and 290:
256 10 Phage Display Technology for
- Page 291 and 292:
258 10 Phage Display Technology for
- Page 293 and 294:
260 10 Phage Display Technology for
- Page 295 and 296:
262 10 Phage Display Technology for
- Page 297 and 298:
264 10 Phage Display Technology for
- Page 299 and 300:
266 10 Phage Display Technology for
- Page 301 and 302:
268 10 Phage Display Technology for
- Page 303 and 304:
270 10 Phage Display Technology for
- Page 305 and 306:
272 10 Phage Display Technology for
- Page 307 and 308:
11 Development of Proteinaceous Dru
- Page 309 and 310:
carrier is an homogenous product. I
- Page 311 and 312:
11.3 The Homing Device 11.3 The Hom
- Page 313 and 314:
malian cell lines that have acquire
- Page 315 and 316:
jugates for the delivery of other a
- Page 317 and 318:
11.5 The Linkage Between Drug and C
- Page 319 and 320:
actions are directed towards these
- Page 321 and 322:
11.5 The Linkage Between Drug and C
- Page 323 and 324:
homing potential if the antigen rec
- Page 325 and 326:
ly used promoters include T7 RNA po
- Page 327 and 328:
the baculovirus expression vector,
- Page 329 and 330:
11.8 Recombinant DNA Constructs 297
- Page 331 and 332:
11.8 Recombinant DNA Constructs 299
- Page 333 and 334:
toxic activity. Anthrax and tetanus
- Page 335 and 336:
11.9 Recombinant Domains as Buildin
- Page 337 and 338:
References 305 [16] Milstein C, Wal
- Page 339 and 340:
References 307 [99] Verma R, Boleti
- Page 341 and 342:
12 Use of Human Tissue Slices in Dr
- Page 343 and 344:
are also extensively used in a vari
- Page 345 and 346:
Meanwhile many incubation systems h
- Page 347 and 348:
12.3 Incubation and Culture of Live
- Page 349 and 350:
to investigate the effect of differ
- Page 351 and 352:
The mechanisms of uptake and excret
- Page 353 and 354:
12.6 The Use of Liver Slices in Dru
- Page 355 and 356:
12.7 Efficacy Testing of the Drug T
- Page 357 and 358:
NO x µM 80 60 40 20 * * 12.7 Effic
- Page 359 and 360:
TNFα ng/ml 1.5 1 0.5 0 * Human (n=
- Page 361 and 362:
References 329 [33] Ikejima K, Enom
- Page 363 and 364:
References 331 [109] Dutt A, Priebe
- Page 365 and 366:
334 13 Pharmacokinetic/Pharmacodyna
- Page 367 and 368:
336 13 Pharmacokinetic/Pharmacodyna
- Page 369 and 370:
338 13 Pharmacokinetic/Pharmacodyna
- Page 371 and 372:
340 13 Pharmacokinetic/Pharmacodyna
- Page 373 and 374:
342 13 Pharmacokinetic/Pharmacodyna
- Page 375 and 376:
344 13 Pharmacokinetic/Pharmacodyna
- Page 377 and 378:
346 13 Pharmacokinetic/Pharmacodyna
- Page 379 and 380:
348 13 Pharmacokinetic/Pharmacodyna
- Page 381 and 382:
350 13 Pharmacokinetic/Pharmacodyna
- Page 383 and 384:
352 13 Pharmacokinetic/Pharmacodyna
- Page 385 and 386:
354 13 Pharmacokinetic/Pharmacodyna
- Page 387 and 388:
356 13 Pharmacokinetic/Pharmacodyna
- Page 389 and 390:
358 13 Pharmacokinetic/Pharmacodyna
- Page 391 and 392:
360 13 Pharmacokinetic/Pharmacodyna
- Page 393 and 394:
362 13 Pharmacokinetic/Pharmacodyna
- Page 395 and 396:
364 13 Pharmacokinetic/Pharmacodyna
- Page 397 and 398:
366 13 Pharmacokinetic/Pharmacodyna
- Page 399 and 400:
368 13 Pharmacokinetic/Pharmacodyna
- Page 401 and 402:
370 13 Pharmacokinetic/Pharmacodyna
- Page 403 and 404:
372 14 Drug Targeting Strategy: Scr
- Page 405 and 406:
374 14 Drug Targeting Strategy: Scr